Vanguard Group Inc Cidara Therapeutics, Inc. Transaction History

Vanguard Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.68 - $0.97 $36,930 - $52,680	54,310 Added 1.65%	3,346,260 $2.64 Million
Q3 2023 Nov 14, 2023	BUY	$0.77 - $1.16 $65,705 - $98,985	85,332 Added 2.66%	3,291,950 $3.09 Million
Q1 2023 May 15, 2023	BUY	$0.75 - $1.98 $553,101 - $1.46 Million	737,468 Added 29.87%	3,206,618 $4.07 Million
Q4 2022 Feb 10, 2023	BUY	$0.48 - $13.08 $584 - $15,918	1,217 Added 0.05%	2,469,150 $1.88 Million
Q3 2022 Nov 14, 2022	BUY	$0.45 - $13.0 $2,835 - $81,900	6,300 Added 0.26%	2,467,933 $1.55 Million
Q1 2022 May 13, 2022	SELL	$0.67 - $1.39 $10,275 - $21,318	-15,337 Reduced 0.62%	2,461,633 $2.05 Million
Q4 2021 Feb 14, 2022	BUY	$1.18 - $2.18 $574,189 - $1.06 Million	486,601 Added 24.45%	2,476,970 $3.15 Million
Q3 2021 Nov 12, 2021	BUY	$1.48 - $2.35 $5,814 - $9,233	3,929 Added 0.2%	1,990,369 $4.46 Million
Q2 2021 Aug 13, 2021	BUY	$1.87 - $2.7 $3.71 Million - $5.36 Million	1,986,440 New	1,986,440 $4.01 Million

Ticker CDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,075,696
Market Cap $1.43B
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.